Found 1730 with Last Name = 'crew' and Initial = 'ap' TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.260nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.270nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.290nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.300nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.350nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.670nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.800nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.910nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.30nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.30nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Inhibition of TBK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.60nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.70nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.30nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Osi Pharmaceuticals
Curated by ChEMBL
Osi Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of truncated TAK1-TAB1(unknown origin) using MKK7 as substrate by ALPHAScreen assay in presence of ATPMore data for this Ligand-Target Pair
3D Structure (crystal)TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.20nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 4.70nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 5.5nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 7.5nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 8.30nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 8.40nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetInhibitor of nuclear factor kappa-B kinase subunit epsilon(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 8.70nMAssay Description:Inhibition of IKKepsilon (unknown origin)More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Osi Pharmaceuticals
Curated by ChEMBL
Osi Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of TAK1-TAB1 (unknown origin) by alphascreen assay in presence of ATPMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 9.80nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7(Homo sapiens (Human))
Osi Pharmaceuticals
Curated by ChEMBL
Osi Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of TAK1 in human HCT116 cells assessed as inhibition of TNF-alpha-stimulated JNK phosphorylationMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of ACK1 (unknown origin) by cellular mechanistic assayMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7(Homo sapiens (Human))
Osi Pharmaceuticals
Curated by ChEMBL
Osi Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of TAK1 in human HCT116 cells assessed as inhibition of TNF-alpha-stimulated JNK phosphorylationMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Osi Pharmaceuticals
Curated by ChEMBL
Osi Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of truncated TAK1-TAB1(unknown origin) using MKK7 as substrate by ALPHAScreen assay in presence of ATPMore data for this Ligand-Target Pair
